HTDS “Negotiating to Merge with a UK Health Care Company”

The secondary or "retail" product line is the devel=
opment of a=20
cosmeticeutical method enabling painless removal of pigmented=
=20
moles from the face and body. Through their branch company in=
=20
Spain (ReNuYu Espana Biochem SA) they plan to offer a "d=
ay clinic=20
spa type" facility and service in Marbella Spain where=
=20
clients can painlessly and with non surgical means remove=20
birthmarks.

EAST EUROPE Biochem is involved aiding in the research and=20
development of "Interferon  Apha". Simply put,=
Interferon alpha is=20
purified polypeptide, which is prepared from leukocytes of a=
=20
peripheral healthy human blood. Interferon is the first natur=
al=20
human body defense from foreign substances  as microorga=
nisms,=20
tumors, and antigenes. Beside antiviral effects, interferon p=
lays=20
an important role in the battle against tumors and with other=
s=20
cytokines take part in various processes in a human body. Thi=
s=20
medicine is used in the forms of injections, cream and eye dr=
ops.

The medical application being currently financed is a $42.4 bil=
lion=20
sector of the market in the US alone. A competing drug Virazole=
with=20
lesser results than EAST EUROPE Biochem went from zero to $964=
=20
million in sales in less than two years. The money being raised=
for=20
the company currently is to enhance and develop these medical=
=20
applications and to =93roll out=94 the non surgical cosmetics i=
n=20
infomercials and hire an executive team to develop broader=20
distribution, brand the product and develop and deliver other=
=20
cosmetic applications.

The idea is that while the development of the Virazole drug is =
being=20
conducted and to preserve the profitability level the company p=
lans=20
to offer day NON surgical solutions to clients in Marbella Spai=
n.=20
The medical applications will be tested and patented further in=
the=20
future as soon as the company is solidly in the black. The wind=
ow of=20
opportunity for exploiting the cosmetic applications of the bio=
chem=20
is now!!!!

The management estimates are that EAST EUROPE has a three =
to five=20
year biotechnological lead on competitors. Once the Company’s=
=20
products are branded and market share secured, EAST EUROPE show=
s=20
major potential to become a leading cosmeceutical and phar=
maceutical=20
company for years to come. EAST EUROPE Biochem has made arrange=
ments=20
to reintroduce its cosmetic applications through infomercials d=
uring=20
Q3 of 2007, and begin operations with a Day NON surgical clinic=
in=20
Marbella Spain.

CNS DAMAGE

Injuries to the head and brain most commonly result from auto=
=20
accidents or gunshot wounds, occasionally from falls or sports=
=20
mishaps. They are most common in the young adult population; au=
to=20
accidents are the leading cause to disability and death in men =
and=20
women under 30.  These consequences have been reduced=20
by an enforcement speed of a 55 m.p.h. speed limit an=
d the use of=20
seat belts.  Helmets for bicyclist and motorcyclists, and =
safer=20
athletic equipment have also reduced the toll.

Brain injury occurs when the brain impacts against the bony sku=
ll,=20
resulting in bruises or lacerations that can have permanent=20
effects. Or there may be bleeding within the brain or over its =
entire=20
surface. Sometimes the injured brain swells with edema fluid,=
=20
putting pressure on the cells. There may also be damage if an o=
bject=20
penetrates the skull and brain or from a depressed skull fractu=
re=20
which bruises the brain beneath it.

Mild brain injury that merely stuns and dazes is called a=20
concussion. Most head injury falls into this category. The pers=
on=20
may be confused, dizzy, forgetful of the preceding events, and =
may=20
vomit. He may briefly lose consciousness. Mild injury seldom ca=
uses=20
permanent damage, although some patients may experience dizzine=
ss,=20
nervousness, restlessness, and headache for weeks or months=20
afterward.

Unconsciousness following a head injury requires prompt medical=
=20
evaluation by a neurologist or neurosurgeon. So do persistent=
=20
vomiting, dilation of one pupil, weakness of the limbs, paralys=
is=20
and convulsions. In fact, it is wise for anyone who has had a b=
rain=20
injury, unless it is trivial to have a neurological examination=
,=20
including an X ray and possibly a computerized cranial tomogram=
(CT=20
scan) to rule out fracture and head off delayed consequences. S=
ome=20
brain injuries, with or without fracture, can cause lasting=20
damage. When a person is rendered unconscious the brain has bee=
n=20
injured. The patient may recover completely, but may develop=20
intracranial bleeding or fluid build up which requires emergenc=
y=20
neurosurgery.

Multiple sclerosis

Multiple sclerosis (abbreviated MS , also known as disseminated=
=20
sclerosis ) is a chronic, inflammatory disease that affects the=
=20
central nervous system (CNS). MS can cause a variety of symptom=
s,=20
including changes in sensation, visual problems, muscle weaknes=
s,=20
depression, difficulties with coordination and speech, severe=
=20
fatigue, and pain. Although many patients lead full and rewardi=
ng=20
lives, MS can cause impaired mobility and disability in more se=
vere=20
cases.

Multiple Sclerosis affects neurons, the cells of the brain and=
=20
spinal cord that carry information, create thought and percepti=
on,=20
and allow the brain to control the body. Surrounding and protec=
ting=20
some of these neurons is a fatty layer known as the myelin shea=
th,=20
which helps neurons carry electrical signals. MS causes gradual=
=20
destruction of myelin (demyelination) and transection of neuron=
=20
axons in patches throughout the brain and spinal cord. The name=

multiple sclerosis refers to the multiple scars (or scleros=
es)=20
on the myelin sheaths. This scarring causes symptoms which vary=
=20
widely depending upon which signals are interrupted. It is thou=
ght=20
that MS results from attacks by an individual’s immune system o=
n the=20
nervous system and is therefore categorized as an autoimmune=20
disease.

Multiple sclerosis may take several different forms, with new=
=20
symptoms occurring either in discrete attacks or slowly accruin=
g=20
over time. Between attacks, symptoms may resolve completely, bu=
t=20
permanent neurologic problems often persist. Although much is k=
nown=20
about how MS causes damage, its exact cause remains unknown. MS=
=20
currently does not have a cure, though several treatments are=
=20
available which may slow the appearance of new symptoms. MS=20
primarily affects adults, with an age of onset typically betwee=
n 20=20
and 40 years, and is more common in women than in men.

Oncogenic Viruses

Dr. Stankovic, specialist-transfusiologist is currently working=
in=20
the "Investigation of morphology, viability and human leuk=
ocytes=20
income prepared from buffy-coat and intended for production of=
=20
interferon-alpha".

Interferon is the powerful antiviral medicine which is successf=
ully=20
used in the treatment offollowingdiseases like varicella zoster=
,=20
herpes simplex, chronic active hepatitis type B, chronic active=
=20
hepatitis type C, Kaposi’s sarcoma connected with HIV infection=
,=20
papilloma viruses, dilation of cardiomyopathy which is caused=
=20
by myocarditis viruses. Interferon affects inhibitory on the gr=
owth=20
of oncogenic viruses, so it justifiably bears a name of: "=
antitumor=20
agent" and it is successfully used in the treatment of mal=
ignant=20
diseases like chronic myelocyte leukemia and hair cells leukemi=
a.=20
Massive production of human interferon preparations couldn’t sa=
tisfy=20
all greater demands in production of this humane preparation fr=
om=20
humane leukocytes.

By the method of genetic engineering, Taniguishi and his resear=
ch=20
fellows succeeded in cloning of human interferon genes, so grea=
t=20
quantity of recombinant interferon alpha was obtained.

EAST EUROPE is involved aiding in the research and development =
of=20
"Interferon Apha". Simply put, Interferon, Human=
Leukocyte=20
Interferon Alpha is a purified polypeptide, prepared from =
leukocytes=20
of a peripheral healthy human blood. Interferon is the first na=
tural=20
human body defense from foreign substances as microorganis=
ms,=20
tumors, and antigenes. Beside antiviruses effects, interferon h=
as an=20
important part in the battle against tumors and with others=20
cytokines take part in various processes in a human body. This=
=20
medicine is used in the forms of injections, cream and eye drop=
s.

Birth Marks

Moles

Moles are raised, usually discolored (pigmented) spots on the s=
kin.=20
They are generally small and round, and most commonly brown,=20
although they may be black or non-pigmented. More than 95%of ad=
ults=20
have at least one mole. Some people have only a few others have=
=20
hundreds. They may be apparent at birth or may become visible d=
uring=20
the first few years of life. Moles commonly enlarge from adoles=
cence=20
through the twenties and during pregnancy. They should be remov=
ed if=20
they are repeatedly bumped or irritated, if they have an undesi=
rable=20
cosmetic appearance, or if they undergo changes that suggest=20
malignancy.

Moles represent proliferations of nevus cells. These cells have=
the=20
same developmental origins as melanocytes, the pigmented produc=
ing=20
cells of the epidermis. Nevus cells are located in the dermisor=
=20
along the epidermal-dermal junction. Like melanocytes, they usu=
ally=20
produce melanin giving most moles their brown color. Some Nevus=
cells=20
are less active in producing melanin, and the moles that they f=
orm=20
are not obviously pigmented.

CORPORATE LEADERSHIP

=B7 Company Officers

Keith Roberts, Interim CEO, CFO
Ivana Crnomarkovic, COO, Europe, COO, Manuf. Ops.
Cathy Zhao, Chief Admin. Officer
Andrea Zecevic-Rubio, Chief Project Scientist, Director, R&=
D

=B7 Number of Employees

11 as of Dec 30, 2008

CORPORATE DATA:

=B7 OTC Market Tier

Pink Sheets Limited

=B7 Primary SIC =97 Industry Classification

8071 – Medical laboratories

=B7 Business Stage

Development Stage Company

=B7 State Of

Incorporation

FL

=B7 Jurisdiction Of Incorporation

United States

=B7 Year Of Incorporation

1993

=B7 Dividends

Div: Spin off; One share Cavit Sciences, Inc. for every 100 shs=
Com
Ex-Date: Jun 9, 2006
Pay Date: Oct 19, 2006
Record Date: Jun 13, 2006